167 related articles for article (PubMed ID: 20953648)
1. Anti-tubercular drug designing by structure based screening of combinatorial libraries.
Ghosh P; Bagchi MC
J Mol Model; 2011 Jul; 17(7):1607-20. PubMed ID: 20953648
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling.
Nandi S; Ahmed S; Saxena AK
SAR QSAR Environ Res; 2018 Feb; 29(2):151-170. PubMed ID: 29347843
[TBL] [Abstract][Full Text] [Related]
3. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
[No Abstract] [Full Text] [Related]
4. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis.
Minovski N; Perdih A; Novic M; Solmajer T
J Comput Chem; 2013 Apr; 34(9):790-801. PubMed ID: 23280926
[TBL] [Abstract][Full Text] [Related]
5. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
[TBL] [Abstract][Full Text] [Related]
6. Design of novel quinoline-aminopiperidine derivatives as
Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
8. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
Adeniji SE
Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR studies and shape based virtual screening for identification of novel hits to inhibit MbtA in Mycobacterium tuberculosis.
Maganti L; ; Ghoshal N
J Biomol Struct Dyn; 2015; 33(2):344-64. PubMed ID: 24417439
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
[TBL] [Abstract][Full Text] [Related]
12. Identification of Potent DNA Gyrase Inhibitors Active against
Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
[No Abstract] [Full Text] [Related]
13. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
Mdluli K; Ma Z
Infect Disord Drug Targets; 2007 Jun; 7(2):159-68. PubMed ID: 17970226
[TBL] [Abstract][Full Text] [Related]
14. Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase.
Kumar A; Siddiqi MI
J Mol Model; 2010 May; 16(5):877-93. PubMed ID: 19779936
[TBL] [Abstract][Full Text] [Related]
15. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
[TBL] [Abstract][Full Text] [Related]
16. Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment.
Minovski N; Perdih A; Solmajer T
J Mol Model; 2012 May; 18(5):1735-53. PubMed ID: 21833830
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
Maharaj Y; Soliman ME
Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
[TBL] [Abstract][Full Text] [Related]
18. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
[TBL] [Abstract][Full Text] [Related]
20. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
